Correlation between overall survival and growth modulation index in pre-treated sarcoma patients: a study from the French Sarcoma Group

Ducimetière, 2011, Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing, PLoS ONE, 6, e20294, 10.1371/journal.pone.0020294 Clark, 2005, Soft-tissue sarcomas in adults, N Engl J Med, 353, 701, 10.1056/NEJMra041866 Verweij, 1995, The present state of the art in chemotherapy for soft tissue sarcomas in adults: the EORTC point of view, Crit Rev Oncol Hematol, 20, 193, 10.1016/1040-8428(94)00146-K Sleijfer, 2005, Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care, Oncologist, 10, 833, 10.1634/theoncologist.10-10-833 Penel, 2011, Br J Cancer, 104, 1544, 10.1038/bjc.2011.136 Demetri, 2009, Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules, J Clin Oncol, 27, 4188, 10.1200/JCO.2008.21.0088 Pautier, 2012, Oncologist, 17, 1213, 10.1634/theoncologist.2011-0467 Sleijfer, 2009, J Clin Oncol, 27, 3126, 10.1200/JCO.2008.21.3223 Van Der Graaf, 2012, Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial, Lancet, 379, 1879, 10.1016/S0140-6736(12)60651-5 Schöffski, 2011, Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes, Lancet Oncol, 12, 1045, 10.1016/S1470-2045(11)70230-3 Leahy, 2007, Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the european organisation for research and treatment of cancer soft tissue and bone sarcoma group, Eur J Cancer, 43, 308, 10.1016/j.ejca.2006.09.014 Garcia del Muro, 2005, A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the spanish group for research on sarcomas, Cancer, 104, 1706, 10.1002/cncr.21384 Penel, 2011, Testing new regimes in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years, Ann Oncol, 22, 1266, 10.1093/annonc/mdq608 Simon, 1994, New designs for the selection of treatments to be tested in randomized clinical trials, Stat Med, 13, 1375, 10.1002/sim.4780130506 Rubinstein, 2005, Design issues of randomized phase II trials and a proposal for phase II screening trials, J Clin Oncol, 23, 7199, 10.1200/JCO.2005.01.149 Eisenhauer, 2009, New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 Von Hoff, 1998, There are no bad anticancer agents, only bad clinical trial design- twenty-first richard and hinda rosenthal foundation award lecture, Clin Cancer Res, 4, 1079 Mick, 2000, Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint, Contr Clin Trials, 21, 343, 10.1016/S0197-2456(00)00058-1 Kovalchik, 2011, Statistical methods for a phase II oncology trial with growth modulation index (GMI) endpoint, Contemp Clin Trials, 32, 99, 10.1016/j.cct.2010.09.010 Cousin, 2012, A paradigm shift in tumour response evaluation of targeted therapy: the assessment of novel drugs in exploratory clinical trials, Curr Opin Oncol, 24, 338, 10.1097/CCO.0b013e3283528b73 Van Gabbeke, 2002, Progression-free rate as the primary endpoint for phase II study in soft tissue sarcoma, Eur J Cancer, 38, 543, 10.1016/S0959-8049(01)00398-7 Bonetti, 2011, Use of the ratio of time to progression following first- and second-line therapy to document the activity of the combination of oxaliplatin with 5-fluorouracil in the treatment of colorectal carcinoma, Ann Oncol, 12, 187, 10.1023/A:1008354909478 Von Hoff, 2010, Pilot study using molecular profiling of patient's tumors to find potential targets and select treatments for their refractory cancers, J Clin Oncol, 28, 4877, 10.1200/JCO.2009.26.5983 Comella, 2002, Oxaliplatin plus raltitrexed and leucovorin-modulated 5-fluorouracil i.v. bolus: a salvage regimen for colorectal cancer patients, Br J Cancer, 86, 1871, 10.1038/sj.bjc.6600414 Zalcberg, 2005, Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg, Eur J Cancer, 41, 1751, 10.1016/j.ejca.2005.04.034 Tournigand, 2004, FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study, J Clin Oncol, 22, 229, 10.1200/JCO.2004.05.113 Penel, 2013, Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as salvage therapy, Ann Oncol, 24, 537, 10.1093/annonc/mds470 Buyse, 2011, Progression-free survival ratio as endpoint for phase II trials in advanced solid tumors, J Clin Oncol, 29, e451, 10.1200/JCO.2010.34.0380